Orthopedic Disorder, Pain, Postoperative Pain, Total Knee Arthroplasty, Total Knee Replacement
Conditions
Keywords
electrical stimulation, neurostimulation, TKA pain, pain following total knee replacement, total knee arthroplasty
Brief summary
The purpose of this study is to determine if electrical stimulation (small levels of electricity) in addition to the standard of care can safely and effectively reduce pain following total knee replacement more than the standard of care, alone. This study involves a device called the SPRINT Beta System. The SPRINT Beta System delivers mild electrical stimulation to nerves in the leg that received the knee replacement. The SPRINT Beta System includes a small wire (called a lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator). About half the subjects in this study will receive the SPRINT Beta system (treatment group) and half will not (control group). Both groups will receive the standard of care.
Interventions
The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator).
Sponsors
Study design
Intervention model description
Half of the subjects enrolled will be randomized (like flipping a coin) to the treatment group and half will be randomized to the control group. Both groups will receive the standard of care for pain management following total knee replacement surgery. Subjects in the treatment group will receive SPR's SPRINT Beta Peripheral Nerve Stimulation (PNS) System in addition to standard of care.
Eligibility
Inclusion criteria
Key Inclusion Criteria: * Scheduled to undergo a primary unilateral total knee replacement procedure Key
Exclusion criteria
* Body Mass Index \> 40 kg/m2 * Conditions that place the subject at increased risk of infection * History of valvular heart disease * Implanted electronic device * Bleeding disorder * Allergy to skin surface electrodes and/or medical-grade adhesive tapes * Pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Average Knee Pain While Walking | Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA) | All subjects were asked to complete daily diaries to record their average pain intensity while walking during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. For each subject, the mean score for each diary period was calculated and a mean of all four diary periods was calculated (weeks 1-4). The mean group scores for weeks 1-4 are reported. |
| Number of Subjects That Experienced at Least One Study-Related Adverse Event | 30 months (from when the first Treatment Group subject enrolled to when the last Treatment Group subject completed the study) | At each study visit following the baseline assessment at Visit 1, subjects were questioned if any changes in their medical status or condition has occurred since their previous visit. If the subject experienced a change that was an adverse event, an Adverse Event Form was completed by the site. The number of Treatment Group subjects that experienced at least one study-related adverse event is reported here. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain Right Now as Measured by the Brief Pain Inventory | Baseline (Visit 2a/2b), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 4 (in-hospital), Visit 6 (2-weeks post TKA), and Visit 8 (4-weeks post TKA) | Subjects were asked to rate their pain right now on an 11-point numerical scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The median score for each time point is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects. For Treatment Group subjects for Visits 3, 4, 6, and 8, pain right now was assessed while peripheral nerve stimulation was on for at least one Lead. For Visit 4, the score reported during the last in-hospital day was used. |
| Amount of Analgesic Usage | Visits 5-8 (weeks 1-4 post-Total Knee Arthroplasty (TKA)) | Subjects recorded the amount/type of analgesics used in daily diaries. Narcotic usage was converted into morphine milligram equivalents (MME). Diaries were collected at various visits and were translated into post-operative days. The average MME was calculated for each subject for the first 28 days (4 weeks) following surgery, and the median of these averages across subjects was determined. If subjects had ceased opioid use (per the Recovery Milestones log), then missing scores following the date of opioid cessation were replaced with 0 MME. If diary entries were missing but the subject had not yet reported opioid cessation, then the missing value was replaced with the mean usage of the available days for the corresponding week. Subjects missing data from one or more entire diaries (i.e., weeks) and had not yet reported opioid cessation by the date of any missing diary were not included in this analysis. |
| Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Baseline (Visit 2a/2b), Visits 4-11 (in-hospital days through 12-months post-Total Knee Arthroplasty (TKA)) | Throughout the study, subjects were asked if they experienced any side effects related to opioid pain medications. The occurrences of these side effects were recorded and were not considered Adverse Events. The number of subjects that experienced at least one opioid-related side effect at each visit is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects. |
| Timed Up and Go (TUG) Test | Visit 1 (Baseline), Visit 4 (In-Hospital), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks Post-TKA) | Subjects began this test from a seated position in a standard chair and were timed while they stood up, walked to a marked point 10 feet away (at a normal, safe pace), returned to the chair, and sat down. Timed Up and Go (TUG) test times are expected to be greater immediately after surgery as compared to baseline. |
| Six Minute Walk Test (6MWT) | Visit 1 (Baseline), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks post-TKA) | The total distance that a subject could walk in 6 minutes was recorded, and subjects unable to walk at all were given a score of 0 meters. The median distance was then determined across subjects. 6 Minute Walk Test distances are expected to be reduced immediately after surgery as compared to baseline. |
| Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 1 (Baseline), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 10 (3-months post-TKA), and Visit 11 (12-months post-TKA) | The Western Ontario McMaster University Osteoarthritis Index (WOMAC) questionnaire consists of 24 items that evaluate pain, stiffness, and physical functional disability. Each item is scored on an 11-point numerical rating scale from 0 to 10, where higher scores indicate greater pain, stiffness, and disability. For each subject, the scores from each of the 24 items were summed to calculate the subject's total score, with a minimum score of 0 and a maximum score of 240. The mean total score was then calculated across subjects for each time point. |
| Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visits 3-11 (Day of Total Knee Arthroplasty (TKA) through 12-months post-TKA) | The Patient Global Impression of Change (PGIC) asks subjects to rate their improvement with treatment on a 7-point scale ranging from very much worse to very much improved as compared to before their knee replacement surgery. The subjects combine all the components of their experience into one overall score. Ratings of Much- or Very Much Improved are considered Meaningful Improvements; similarly, ratings of Much- or Very Much Worse are categorized as Meaningfully Worse. Ratings of Minimally Improved, No Change, or Minimally Worse are considered Minimal or No Change. |
| Pain Catastrophizing Scale (PCS) | Visit 1 (Baseline), Visit 8 (4 weeks post-Total Knee Arthroplasty (TKA)), Visit 10 (3-months Post-TKA) | The Pain Catastrophizing Scale (PCS) questionnaire has 13 questions that assess rumination, magnification, and helplessness. Subjects are asked to think back on painful experiences in the past and reflect on how often they had specific thoughts or feelings. Each of the 13 questions is scored on a 5-point scale where 0 represents not at all, and 4 represents all the time. The scores from each question were summed for each subject to provide a total PCS score, with a possible range from 0 to 52 with higher scores indicating a greater tendency to catastrophize pain (i.e. a higher score indicates a worse outcome). The median scores were then calculated across all subjects. |
| Average Knee Pain Over the Last 24 Hours | Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA)) | All subjects were asked to complete daily diaries to track their average pain intensity during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported. |
| Subject Satisfaction Survey | Visit 8 (4-weeks post-total knee arthroplasty (TKA)) | Subjects completed a sponsor-developed survey with questions pertaining to their feelings about the treatment they received following total knee arthroplasty (TKA) surgery. Treatment Group subjects were asked to report on their experience using the SPRINT Beta Stimulation System as a method for managing post-surgical pain. Depending on the question, subjects were asked to indicate their agreement with the question (strongly disagree, agree, neutral, disagree, strongly disagree), their comfort with the therapy (very uncomfortable, a little bit uncomfortable, fairly comfortable, very comfortable), or when pain relief was felt (immediately, a few minutes later, a few hours later, more than a day later or never). Responses are presented for Treatment Group subjects for key groups of questions related to the therapy whereby answer options are considered affirmative for strongly agree/agree, very easy/easy, very comfortable/comfortable. |
| Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 5 (1-week post-Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 7 (3-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 9 (2-months post-TKA), and Visit 10 (3-months post-TKA) | Following discharge after total knee arthroplasty (TKA) surgery, subjects were asked to report how many physical therapy sessions they attended since the previous study visit. The median number of physical therapy sessions attended is reported for each group at each time point. |
| Subject's Use of Device (Compliance) | Visit 4 (In-Hospital), Visit 6 (2-weeks post-Total Knee Arthroplasty (TKA)), and Visit 8 (4-weeks Post-TKA) | The hours of usage were recorded for each Lead (femoral and sciatic) from the SPRINT Beta stimulator throughout the study to assess the level of subject compliance with the peripheral nerve stimulation therapy. Treatment Group subjects were asked to use the device for up to 24 hrs each day. The stimulator provided the cumulative number of hours in use since the device was activated. For each timepoint for Treatment Group participants (subjects who received stimulation therapy), the median cumulative number of hours of use for each lead is presented for each timepoint. |
| Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | 1-week post-Total Knee Arthroplasty (TKA) | Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. Questions regarding experience with in-hospital pain management are reported below. |
| Inpatient Pain Management Experience Survey (Pain Medicine During Hospital Stay) | 1-week post-Total Knee Arthroplasty (TKA) | Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The number of subjects that responded affirmatively to the following question are reported below: During this hospital stay, did you need medicine for pain? |
| Inpatient Pain Management Experience Survey (Discharge Facility) | 1-week post-Total Knee Arthroplasty (TKA) | Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The question regarding discharge location following hospital stay is reported below. |
| Inpatient Pain Management Experience Survey (Overall Rating of Hospital) | 1-week post-Total Knee Arthroplasty (TKA)) | Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. As part of this survey, subjects were asked to rate their hospital stay on an 11-point numerical rating scale where 0 represents worst hospital possible and 10 represents best hospital possible. The median score for each group is reported. |
| Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | From Day of Surgery through completion of milestone or 12-months from Day of Surgery, whichever came first | Participants were queried at each visit from the date of their Total Knee Arthroplasty (TKA) until they met specific, post-surgical recovery milestones. Participants were queried up through the time at which they met each milestone or through their completion of the study, whichever came first (up to twelve months post-surgery). For each milestone, the median number of days between the date of TKA and date to achieve the milestone was calculated. |
| Average Knee Pain at Rest | Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA)) | All subjects were asked to complete daily diaries to track their average pain intensity at rest during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported. |
Countries
United States
Participant flow
Recruitment details
Recruitment began in July 2017 (with first subject enrollment in September 2017) and was concluded in February 2020. Subjects were screened from the available pool of candidates scheduled to undergo a primary unilateral total knee replacement procedure.
Pre-assignment details
After obtaining informed consent, subjects were evaluated for eligibility.
Participants by arm
| Arm | Count |
|---|---|
| Treatment Group Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | 18 |
| Control Group Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. | 23 |
| Total | 41 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Consented | Screen failure before enrollment | 4 | 0 | 0 |
| Consented | Screen failure before randomization | 2 | 0 | 0 |
| Consented | TKA cancelled after enrollment | 1 | 0 | 0 |
| Consented | Withdrawn from study | 12 | 0 | 0 |
| Study Enrollment | TKA cancelled after enrollment | 0 | 0 | 1 |
| Study Enrollment | Withdrawn from study | 0 | 6 | 6 |
Baseline characteristics
| Characteristic | Treatment Group | Control Group | Total |
|---|---|---|---|
| Affected Leg Left Leg | 10 Participants | 7 Participants | 17 Participants |
| Affected Leg Right Leg | 8 Participants | 15 Participants | 23 Participants |
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 9 Participants | 11 Participants | 20 Participants |
| Age, Categorical Between 18 and 65 years | 9 Participants | 11 Participants | 20 Participants |
| Age, Continuous | 65.0 years STANDARD_DEVIATION 5.5 | 63.0 years STANDARD_DEVIATION 10.3 | 63.9 years STANDARD_DEVIATION 8.4 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 18 Participants | 21 Participants | 39 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 16 Participants | 21 Participants | 37 Participants |
| Reason for Total Knee Arthroplasty (TKA) Degenerative Joint Disease | 0 Participants | 1 Participants | 1 Participants |
| Reason for Total Knee Arthroplasty (TKA) Osteoarthritis | 16 Participants | 21 Participants | 37 Participants |
| Reason for Total Knee Arthroplasty (TKA) Post-Traumatic Arthritis | 2 Participants | 0 Participants | 2 Participants |
| Region of Enrollment United States | 18 participants | 23 participants | 41 participants |
| Sex: Female, Male Female | 12 Participants | 12 Participants | 24 Participants |
| Sex: Female, Male Male | 6 Participants | 10 Participants | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 18 | 0 / 23 |
| other Total, other adverse events | 12 / 18 | 9 / 23 |
| serious Total, serious adverse events | 2 / 18 | 3 / 23 |
Outcome results
Average Knee Pain While Walking
All subjects were asked to complete daily diaries to record their average pain intensity while walking during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. For each subject, the mean score for each diary period was calculated and a mean of all four diary periods was calculated (weeks 1-4). The mean group scores for weeks 1-4 are reported.
Time frame: Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA)
Population: Per Protocol Set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment Group | Average Knee Pain While Walking | 3.70 Scores on a scale | Standard Deviation 1.97 |
| Control Group | Average Knee Pain While Walking | 4.14 Scores on a scale | Standard Deviation 1.49 |
Number of Subjects That Experienced at Least One Study-Related Adverse Event
At each study visit following the baseline assessment at Visit 1, subjects were questioned if any changes in their medical status or condition has occurred since their previous visit. If the subject experienced a change that was an adverse event, an Adverse Event Form was completed by the site. The number of Treatment Group subjects that experienced at least one study-related adverse event is reported here.
Time frame: 30 months (from when the first Treatment Group subject enrolled to when the last Treatment Group subject completed the study)
Population: All enrolled Treatment Group subjects
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment Group | Number of Subjects That Experienced at Least One Study-Related Adverse Event | 8 Participants |
Amount of Analgesic Usage
Subjects recorded the amount/type of analgesics used in daily diaries. Narcotic usage was converted into morphine milligram equivalents (MME). Diaries were collected at various visits and were translated into post-operative days. The average MME was calculated for each subject for the first 28 days (4 weeks) following surgery, and the median of these averages across subjects was determined. If subjects had ceased opioid use (per the Recovery Milestones log), then missing scores following the date of opioid cessation were replaced with 0 MME. If diary entries were missing but the subject had not yet reported opioid cessation, then the missing value was replaced with the mean usage of the available days for the corresponding week. Subjects missing data from one or more entire diaries (i.e., weeks) and had not yet reported opioid cessation by the date of any missing diary were not included in this analysis.
Time frame: Visits 5-8 (weeks 1-4 post-Total Knee Arthroplasty (TKA))
Population: Per Protocol Set - Data were not available for one Control Group subject at Visits 6-8.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Treatment Group | Amount of Analgesic Usage | Visit 5 (1-week Post-TKA) | 29.9 MME |
| Treatment Group | Amount of Analgesic Usage | Visit 6 (2-weeks Post-TKA) | 21.4 MME |
| Treatment Group | Amount of Analgesic Usage | Visit 7 (3-weeks Post-TKA) | 13.6 MME |
| Treatment Group | Amount of Analgesic Usage | Visit 8 (4-weeks Post-TKA) | 11.4 MME |
| Treatment Group | Amount of Analgesic Usage | Average Across Visits 5-8 | 19.1 MME |
| Control Group | Amount of Analgesic Usage | Average Across Visits 5-8 | 16.8 MME |
| Control Group | Amount of Analgesic Usage | Visit 8 (4-weeks Post-TKA) | 2.9 MME |
| Control Group | Amount of Analgesic Usage | Visit 6 (2-weeks Post-TKA) | 22.5 MME |
| Control Group | Amount of Analgesic Usage | Visit 5 (1-week Post-TKA) | 31.4 MME |
| Control Group | Amount of Analgesic Usage | Visit 7 (3-weeks Post-TKA) | 17.1 MME |
Average Knee Pain at Rest
All subjects were asked to complete daily diaries to track their average pain intensity at rest during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported.
Time frame: Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA))
Population: Per Protocol Set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment Group | Average Knee Pain at Rest | 2.86 score on a scale | Standard Deviation 1.23 |
| Control Group | Average Knee Pain at Rest | 3.48 score on a scale | Standard Deviation 1.33 |
Average Knee Pain Over the Last 24 Hours
All subjects were asked to complete daily diaries to track their average pain intensity during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported.
Time frame: Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA))
Population: Per Protocol Set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment Group | Average Knee Pain Over the Last 24 Hours | 3.24 score on a scale | Standard Deviation 1.52 |
| Control Group | Average Knee Pain Over the Last 24 Hours | 4.32 score on a scale | Standard Deviation 1.34 |
Inpatient Pain Management Experience Survey (Discharge Facility)
Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The question regarding discharge location following hospital stay is reported below.
Time frame: 1-week post-Total Knee Arthroplasty (TKA)
Population: Per Protocol Set - Data were not available for three Control Group subjects.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment Group | Inpatient Pain Management Experience Survey (Discharge Facility) | Someone else's home | 0 Participants |
| Treatment Group | Inpatient Pain Management Experience Survey (Discharge Facility) | Another healthcare facility | 0 Participants |
| Treatment Group | Inpatient Pain Management Experience Survey (Discharge Facility) | Own home | 7 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Discharge Facility) | Someone else's home | 1 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Discharge Facility) | Another healthcare facility | 1 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Discharge Facility) | Own home | 11 Participants |
Inpatient Pain Management Experience Survey (Overall Rating of Hospital)
Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. As part of this survey, subjects were asked to rate their hospital stay on an 11-point numerical rating scale where 0 represents worst hospital possible and 10 represents best hospital possible. The median score for each group is reported.
Time frame: 1-week post-Total Knee Arthroplasty (TKA))
Population: Per Protocol Set - Data were not available for three Control Group subjects.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment Group | Inpatient Pain Management Experience Survey (Overall Rating of Hospital) | 10 score on a scale |
| Control Group | Inpatient Pain Management Experience Survey (Overall Rating of Hospital) | 10 score on a scale |
Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay)
Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. Questions regarding experience with in-hospital pain management are reported below.
Time frame: 1-week post-Total Knee Arthroplasty (TKA)
Population: Per Protocol Set - Data were not available for three Control Group subjects.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Treatment Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During this hospital stay, how often was your pain well controlled? | Never | 0 Participants |
| Treatment Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During this hospital stay, how often was your pain well controlled? | Sometimes | 1 Participants |
| Treatment Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During this hospital stay, how often was your pain well controlled? | Usually | 3 Participants |
| Treatment Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During this hospital stay, how often was your pain well controlled? | Always | 3 Participants |
| Treatment Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During hospital stay, how often did hospital staff do everything they could to help with your pain? | Never | 0 Participants |
| Treatment Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During hospital stay, how often did hospital staff do everything they could to help with your pain? | Sometimes | 0 Participants |
| Treatment Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During hospital stay, how often did hospital staff do everything they could to help with your pain? | Usually | 1 Participants |
| Treatment Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During hospital stay, how often did hospital staff do everything they could to help with your pain? | Always | 6 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During hospital stay, how often did hospital staff do everything they could to help with your pain? | Always | 10 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During this hospital stay, how often was your pain well controlled? | Never | 0 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During hospital stay, how often did hospital staff do everything they could to help with your pain? | Never | 0 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During this hospital stay, how often was your pain well controlled? | Sometimes | 3 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During hospital stay, how often did hospital staff do everything they could to help with your pain? | Usually | 2 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During this hospital stay, how often was your pain well controlled? | Usually | 4 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During hospital stay, how often did hospital staff do everything they could to help with your pain? | Sometimes | 1 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | During this hospital stay, how often was your pain well controlled? | Always | 6 Participants |
Inpatient Pain Management Experience Survey (Pain Medicine During Hospital Stay)
Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The number of subjects that responded affirmatively to the following question are reported below: During this hospital stay, did you need medicine for pain?
Time frame: 1-week post-Total Knee Arthroplasty (TKA)
Population: Per Protocol - Data were not available for three Control Group subjects
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment Group | Inpatient Pain Management Experience Survey (Pain Medicine During Hospital Stay) | 6 Participants |
| Control Group | Inpatient Pain Management Experience Survey (Pain Medicine During Hospital Stay) | 13 Participants |
Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty
Following discharge after total knee arthroplasty (TKA) surgery, subjects were asked to report how many physical therapy sessions they attended since the previous study visit. The median number of physical therapy sessions attended is reported for each group at each time point.
Time frame: Visit 5 (1-week post-Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 7 (3-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 9 (2-months post-TKA), and Visit 10 (3-months post-TKA)
Population: Per Protocol Set - Data were not available for the following Control Group subjects: one at Visit 6, two Visit 9, and three at Visit 10.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Treatment Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 5 (1-week Post-TKA) | 2 Count of visits |
| Treatment Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 6 (2-weeks Post-TKA) | 3 Count of visits |
| Treatment Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 7 (3-weeks Post-TKA) | 2 Count of visits |
| Treatment Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 8 (4-weeks Post-TKA) | 2 Count of visits |
| Treatment Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 9 (2-months Post-TKA) | 9 Count of visits |
| Treatment Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 10 (3-months Post-TKA) | 8 Count of visits |
| Control Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 9 (2-months Post-TKA) | 5 Count of visits |
| Control Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 5 (1-week Post-TKA) | 2 Count of visits |
| Control Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 8 (4-weeks Post-TKA) | 2 Count of visits |
| Control Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 6 (2-weeks Post-TKA) | 3 Count of visits |
| Control Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 10 (3-months Post-TKA) | 6 Count of visits |
| Control Group | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Visit 7 (3-weeks Post-TKA) | 3 Count of visits |
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
The Patient Global Impression of Change (PGIC) asks subjects to rate their improvement with treatment on a 7-point scale ranging from very much worse to very much improved as compared to before their knee replacement surgery. The subjects combine all the components of their experience into one overall score. Ratings of Much- or Very Much Improved are considered Meaningful Improvements; similarly, ratings of Much- or Very Much Worse are categorized as Meaningfully Worse. Ratings of Minimally Improved, No Change, or Minimally Worse are considered Minimal or No Change.
Time frame: Visits 3-11 (Day of Total Knee Arthroplasty (TKA) through 12-months post-TKA)
Population: Per Protocol Set: Data were not available for one Treatment Group subject at Visit 11. Data were not available for the following Control Group subjects: one at Visit 4, one at Visit 6, one at Visit 9, three at Visit 10, and two at Visit 11.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 3 (Day of TKA) | Minimal or No Change | 5 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 3 (Day of TKA) | Meaningfully Worse | 2 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 4 (In-Hospital) | Meaningful Improvement | 1 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 4 (In-Hospital) | Minimal or No Change | 5 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 5 (1-week Post-TKA) | Meaningful Improvement | 2 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 5 (1-week Post-TKA) | Minimal or No Change | 3 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 6 (2-weeks Post-TKA) | Minimal or No Change | 3 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 6 (2-weeks Post-TKA) | Meaningfully Worse | 2 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 7 (3-weeks Post-TKA) | Meaningful Improvement | 2 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 7 (3-weeks Post-TKA) | Minimal or No Change | 3 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 7 (3-weeks Post-TKA) | Meaningfully Worse | 2 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 8 (4-weeks Post-TKA) | Minimal or No Change | 3 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 8 (4-weeks Post-TKA) | Meaningfully Worse | 2 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 9 (2-months Post-TKA) | Minimal or No Change | 3 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 10 (3-months Post-TKA) | Meaningful Improvement | 6 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 10 (3-months Post-TKA) | Minimal or No Change | 1 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 10 (3-months Post-TKA) | Meaningfully Worse | 0 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 11 (12-months Post-TKA) | Meaningful Improvement | 6 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 4 (In-Hospital) | Meaningfully Worse | 1 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 5 (1-week Post-TKA) | Meaningfully Worse | 2 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 6 (2-weeks Post-TKA) | Meaningful Improvement | 2 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 8 (4-weeks Post-TKA) | Meaningful Improvement | 2 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 9 (2-months Post-TKA) | Meaningful Improvement | 4 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 9 (2-months Post-TKA) | Meaningfully Worse | 0 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 11 (12-months Post-TKA) | Minimal or No Change | 0 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 11 (12-months Post-TKA) | Meaningfully Worse | 0 Participants |
| Treatment Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 3 (Day of TKA) | Meaningful Improvement | 0 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 9 (2-months Post-TKA) | Minimal or No Change | 7 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 3 (Day of TKA) | Meaningful Improvement | 1 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 3 (Day of TKA) | Minimal or No Change | 14 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 9 (2-months Post-TKA) | Meaningfully Worse | 0 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 3 (Day of TKA) | Meaningfully Worse | 1 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 6 (2-weeks Post-TKA) | Meaningful Improvement | 3 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 4 (In-Hospital) | Meaningful Improvement | 4 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 10 (3-months Post-TKA) | Meaningful Improvement | 9 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 4 (In-Hospital) | Meaningfully Worse | 2 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 7 (3-weeks Post-TKA) | Meaningfully Worse | 1 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 5 (1-week Post-TKA) | Meaningful Improvement | 3 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 10 (3-months Post-TKA) | Minimal or No Change | 4 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 5 (1-week Post-TKA) | Minimal or No Change | 11 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 11 (12-months Post-TKA) | Meaningful Improvement | 12 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 6 (2-weeks Post-TKA) | Minimal or No Change | 11 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 10 (3-months Post-TKA) | Meaningfully Worse | 0 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 6 (2-weeks Post-TKA) | Meaningfully Worse | 1 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 8 (4-weeks Post-TKA) | Meaningful Improvement | 6 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 7 (3-weeks Post-TKA) | Meaningful Improvement | 3 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 4 (In-Hospital) | Minimal or No Change | 9 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 7 (3-weeks Post-TKA) | Minimal or No Change | 12 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 8 (4-weeks Post-TKA) | Meaningfully Worse | 1 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 11 (12-months Post-TKA) | Meaningfully Worse | 0 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 8 (4-weeks Post-TKA) | Minimal or No Change | 9 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 5 (1-week Post-TKA) | Meaningfully Worse | 2 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 9 (2-months Post-TKA) | Meaningful Improvement | 8 Participants |
| Control Group | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | Visit 11 (12-months Post-TKA) | Minimal or No Change | 2 Participants |
Number of Subjects That Experienced at Least One Opioid-Related Side Effect
Throughout the study, subjects were asked if they experienced any side effects related to opioid pain medications. The occurrences of these side effects were recorded and were not considered Adverse Events. The number of subjects that experienced at least one opioid-related side effect at each visit is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects.
Time frame: Baseline (Visit 2a/2b), Visits 4-11 (in-hospital days through 12-months post-Total Knee Arthroplasty (TKA))
Population: Per Protocol Set - Data were not available for one Treatment Group subject at Visit 6 and Visit 11.~Data were not available for the following Control Group subjects: one at Visits 5, 6, 7, and 9, and three at Visits 10 and 11.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 11 (12-months Post-TKA) | 0 Participants |
| Treatment Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Baseline | 0 Participants |
| Treatment Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 4 (In-Hospital) | 3 Participants |
| Treatment Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 5 (1-week Post-TKA) | 3 Participants |
| Treatment Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 6 (2-weeks Post-TKA) | 3 Participants |
| Treatment Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 7 (3-weeks Post-TKA) | 2 Participants |
| Treatment Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 8 (4-weeks Post-TKA) | 1 Participants |
| Treatment Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 10 (3-months Post-TKA) | 0 Participants |
| Treatment Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 9 (2-months Post-TKA) | 0 Participants |
| Control Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 11 (12-months Post-TKA) | 0 Participants |
| Control Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 7 (3-weeks Post-TKA) | 6 Participants |
| Control Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Baseline | 0 Participants |
| Control Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 10 (3-months Post-TKA) | 0 Participants |
| Control Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 4 (In-Hospital) | 7 Participants |
| Control Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 8 (4-weeks Post-TKA) | 4 Participants |
| Control Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 5 (1-week Post-TKA) | 9 Participants |
| Control Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 9 (2-months Post-TKA) | 0 Participants |
| Control Group | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Visit 6 (2-weeks Post-TKA) | 8 Participants |
Pain Catastrophizing Scale (PCS)
The Pain Catastrophizing Scale (PCS) questionnaire has 13 questions that assess rumination, magnification, and helplessness. Subjects are asked to think back on painful experiences in the past and reflect on how often they had specific thoughts or feelings. Each of the 13 questions is scored on a 5-point scale where 0 represents not at all, and 4 represents all the time. The scores from each question were summed for each subject to provide a total PCS score, with a possible range from 0 to 52 with higher scores indicating a greater tendency to catastrophize pain (i.e. a higher score indicates a worse outcome). The median scores were then calculated across all subjects.
Time frame: Visit 1 (Baseline), Visit 8 (4 weeks post-Total Knee Arthroplasty (TKA)), Visit 10 (3-months Post-TKA)
Population: Per Protocol Set - Data were not available for three Control Group subjects at Visit 10.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Treatment Group | Pain Catastrophizing Scale (PCS) | Visit 1 (Baseline) | 7 score on a scale |
| Treatment Group | Pain Catastrophizing Scale (PCS) | Visit 8 (4-weeks Post-TKA) | 6 score on a scale |
| Treatment Group | Pain Catastrophizing Scale (PCS) | Visit 10 (3-months Post-TKA) | 1 score on a scale |
| Control Group | Pain Catastrophizing Scale (PCS) | Visit 1 (Baseline) | 7 score on a scale |
| Control Group | Pain Catastrophizing Scale (PCS) | Visit 10 (3-months Post-TKA) | 0 score on a scale |
| Control Group | Pain Catastrophizing Scale (PCS) | Visit 8 (4-weeks Post-TKA) | 4 score on a scale |
Pain Right Now as Measured by the Brief Pain Inventory
Subjects were asked to rate their pain right now on an 11-point numerical scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The median score for each time point is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects. For Treatment Group subjects for Visits 3, 4, 6, and 8, pain right now was assessed while peripheral nerve stimulation was on for at least one Lead. For Visit 4, the score reported during the last in-hospital day was used.
Time frame: Baseline (Visit 2a/2b), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 4 (in-hospital), Visit 6 (2-weeks post TKA), and Visit 8 (4-weeks post TKA)
Population: Per Protocol Set - Data were not available for one Treatment Group subject at Visit 3 and for one Control Group subject at Visit 6.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Treatment Group | Pain Right Now as Measured by the Brief Pain Inventory | Visit 3 (Day of TKA) | 2.0 Scores on a scale |
| Treatment Group | Pain Right Now as Measured by the Brief Pain Inventory | Visit 6 (2-weeks Post-TKA) | 2.0 Scores on a scale |
| Treatment Group | Pain Right Now as Measured by the Brief Pain Inventory | Visit 4 (In-Hospital) | 2.0 Scores on a scale |
| Treatment Group | Pain Right Now as Measured by the Brief Pain Inventory | Visit 8 (4-weeks Post-TKA) | 1.0 Scores on a scale |
| Treatment Group | Pain Right Now as Measured by the Brief Pain Inventory | Baseline | 1.0 Scores on a scale |
| Control Group | Pain Right Now as Measured by the Brief Pain Inventory | Visit 8 (4-weeks Post-TKA) | 1.0 Scores on a scale |
| Control Group | Pain Right Now as Measured by the Brief Pain Inventory | Baseline | 3.0 Scores on a scale |
| Control Group | Pain Right Now as Measured by the Brief Pain Inventory | Visit 3 (Day of TKA) | 2.0 Scores on a scale |
| Control Group | Pain Right Now as Measured by the Brief Pain Inventory | Visit 4 (In-Hospital) | 3.5 Scores on a scale |
| Control Group | Pain Right Now as Measured by the Brief Pain Inventory | Visit 6 (2-weeks Post-TKA) | 3.0 Scores on a scale |
Six Minute Walk Test (6MWT)
The total distance that a subject could walk in 6 minutes was recorded, and subjects unable to walk at all were given a score of 0 meters. The median distance was then determined across subjects. 6 Minute Walk Test distances are expected to be reduced immediately after surgery as compared to baseline.
Time frame: Visit 1 (Baseline), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks post-TKA)
Population: Per Protocol Set - Data were not available for one Control Group subject at Visit 6.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Treatment Group | Six Minute Walk Test (6MWT) | Visit 1 (Baseline) | 458.5 meters |
| Treatment Group | Six Minute Walk Test (6MWT) | Visit 6 (2-weeks Post-TKA) | 280.0 meters |
| Treatment Group | Six Minute Walk Test (6MWT) | Visit 8 (4-weeks Post-TKA) | 410.0 meters |
| Control Group | Six Minute Walk Test (6MWT) | Visit 1 (Baseline) | 351.3 meters |
| Control Group | Six Minute Walk Test (6MWT) | Visit 6 (2-weeks Post-TKA) | 281.0 meters |
| Control Group | Six Minute Walk Test (6MWT) | Visit 8 (4-weeks Post-TKA) | 329.0 meters |
Subject Satisfaction Survey
Subjects completed a sponsor-developed survey with questions pertaining to their feelings about the treatment they received following total knee arthroplasty (TKA) surgery. Treatment Group subjects were asked to report on their experience using the SPRINT Beta Stimulation System as a method for managing post-surgical pain. Depending on the question, subjects were asked to indicate their agreement with the question (strongly disagree, agree, neutral, disagree, strongly disagree), their comfort with the therapy (very uncomfortable, a little bit uncomfortable, fairly comfortable, very comfortable), or when pain relief was felt (immediately, a few minutes later, a few hours later, more than a day later or never). Responses are presented for Treatment Group subjects for key groups of questions related to the therapy whereby answer options are considered affirmative for strongly agree/agree, very easy/easy, very comfortable/comfortable.
Time frame: Visit 8 (4-weeks post-total knee arthroplasty (TKA))
Population: Per Protocol Set
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment Group | Subject Satisfaction Survey | Tolerated Lead placement with some or no discomfort | 7 Participants |
| Treatment Group | Subject Satisfaction Survey | Reported stimulation felt comfortable/soothing | 5 Participants |
| Treatment Group | Subject Satisfaction Survey | Reported immediate pain relief (0-5 minutes) | 4 Participants |
| Treatment Group | Subject Satisfaction Survey | Would recommend therapy to a friend | 7 Participants |
| Treatment Group | Subject Satisfaction Survey | Would want to receive again if having another TKA | 7 Participants |
| Treatment Group | Subject Satisfaction Survey | Prefer stimulation therapy to pain medication use | 7 Participants |
| Treatment Group | Subject Satisfaction Survey | Wanted stimulation for longer time period before TKA surgery | 1 Participants |
| Treatment Group | Subject Satisfaction Survey | Wanted stimulation for longer time period after TKA surgery | 1 Participants |
Subject's Use of Device (Compliance)
The hours of usage were recorded for each Lead (femoral and sciatic) from the SPRINT Beta stimulator throughout the study to assess the level of subject compliance with the peripheral nerve stimulation therapy. Treatment Group subjects were asked to use the device for up to 24 hrs each day. The stimulator provided the cumulative number of hours in use since the device was activated. For each timepoint for Treatment Group participants (subjects who received stimulation therapy), the median cumulative number of hours of use for each lead is presented for each timepoint.
Time frame: Visit 4 (In-Hospital), Visit 6 (2-weeks post-Total Knee Arthroplasty (TKA)), and Visit 8 (4-weeks Post-TKA)
Population: Per Protocol Set - Treatment Group. Data were not available for the femoral or sciatic Leads for one subject at Visit 4 and two subjects at Visit 6. One subject at Visits 4, 6, 8 did not have a sciatic Lead in place.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Treatment Group | Subject's Use of Device (Compliance) | Visit 4 (In-Hospital): Femoral Lead | 79 hours |
| Treatment Group | Subject's Use of Device (Compliance) | Visit 4 (In-Hospital): Sciatic Lead | 73 hours |
| Treatment Group | Subject's Use of Device (Compliance) | Visit 6 (2-weeks Post-TKA): Femoral Lead | 358 hours |
| Treatment Group | Subject's Use of Device (Compliance) | Visit 6 (2-weeks Post-TKA): Sciatic Lead | 373.5 hours |
| Treatment Group | Subject's Use of Device (Compliance) | Visit 8 (4-weeks Post-TKA): Femoral Lead | 646 hours |
| Treatment Group | Subject's Use of Device (Compliance) | Visit 8 (4-weeks Post-TKA): Sciatic Lead | 633 hours |
Timed Up and Go (TUG) Test
Subjects began this test from a seated position in a standard chair and were timed while they stood up, walked to a marked point 10 feet away (at a normal, safe pace), returned to the chair, and sat down. Timed Up and Go (TUG) test times are expected to be greater immediately after surgery as compared to baseline.
Time frame: Visit 1 (Baseline), Visit 4 (In-Hospital), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks Post-TKA)
Population: Per Protocol Set - Data were not available for the following Control Group subjects: one at Visit 1 (subject was unable to complete test), three at Visit 4 (two subjects were unable to complete test), and one at Visit 6.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Treatment Group | Timed Up and Go (TUG) Test | Time at Visit 1 (Baseline) | 12.44 seconds |
| Treatment Group | Timed Up and Go (TUG) Test | Time at Visit 4 (In-Hospital) | 41.80 seconds |
| Treatment Group | Timed Up and Go (TUG) Test | Time at Visit 6 (2-weeks Post-TKA) | 14.28 seconds |
| Treatment Group | Timed Up and Go (TUG) Test | Time at Visit 8 (4-weeks Post-TKA) | 10.68 seconds |
| Control Group | Timed Up and Go (TUG) Test | Time at Visit 8 (4-weeks Post-TKA) | 10.38 seconds |
| Control Group | Timed Up and Go (TUG) Test | Time at Visit 1 (Baseline) | 10.25 seconds |
| Control Group | Timed Up and Go (TUG) Test | Time at Visit 6 (2-weeks Post-TKA) | 15.93 seconds |
| Control Group | Timed Up and Go (TUG) Test | Time at Visit 4 (In-Hospital) | 42.22 seconds |
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)
Participants were queried at each visit from the date of their Total Knee Arthroplasty (TKA) until they met specific, post-surgical recovery milestones. Participants were queried up through the time at which they met each milestone or through their completion of the study, whichever came first (up to twelve months post-surgery). For each milestone, the median number of days between the date of TKA and date to achieve the milestone was calculated.
Time frame: From Day of Surgery through completion of milestone or 12-months from Day of Surgery, whichever came first
Population: Per Protocol Set- Treatment Group: Data were not available for: 1 subject in walked without assistive device, 1 in cleared to drive. 1 subject did not cease opioids during the study. 5 subjects were retired and did not work.~Control Group: Data were not collected for: 3 in walked without assistive device, 2 in able to climb stairs, 1 in cleared to drive, 1 in opioid cessation (2 more did not cease opioids during the study). 9 subjects were retired and did not work.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Treatment Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Discharged from hospital | 1 days |
| Treatment Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Walked without assistive device | 24 days |
| Treatment Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Walked 30 meters | 1 days |
| Treatment Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Able to climb flight of stairs | 1 days |
| Treatment Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Cleared to drive | 21 days |
| Treatment Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Returned to work | 9 days |
| Treatment Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Cessation of all opioid medications | 37 days |
| Treatment Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Walked with assistive device | 0 days |
| Treatment Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Met hospital discharge criteria | 1 days |
| Treatment Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Pain controlled without nerve block | 3 days |
| Control Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Walked with assistive device | 1 days |
| Control Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Pain controlled without nerve block | 2 days |
| Control Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Returned to work | 20 days |
| Control Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Walked without assistive device | 16 days |
| Control Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Able to climb flight of stairs | 13 days |
| Control Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Walked 30 meters | 4 days |
| Control Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Cessation of all opioid medications | 28 days |
| Control Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Discharged from hospital | 1 days |
| Control Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Met hospital discharge criteria | 1 days |
| Control Group | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Cleared to drive | 21 days |
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
The Western Ontario McMaster University Osteoarthritis Index (WOMAC) questionnaire consists of 24 items that evaluate pain, stiffness, and physical functional disability. Each item is scored on an 11-point numerical rating scale from 0 to 10, where higher scores indicate greater pain, stiffness, and disability. For each subject, the scores from each of the 24 items were summed to calculate the subject's total score, with a minimum score of 0 and a maximum score of 240. The mean total score was then calculated across subjects for each time point.
Time frame: Visit 1 (Baseline), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 10 (3-months post-TKA), and Visit 11 (12-months post-TKA)
Population: Per Protocol Set - Data were not available for one Treatment Group subject at Visit 11. Data were not available for the following Control Group subjects: three at Visit 3, one at Visit 6, three at Visit 10, and two at Visit 11.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Treatment Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 11 (12-months Post-TKA) | 4.83 score on a scale | Standard Deviation 4.36 |
| Treatment Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 3 (Day of TKA) | 68.71 score on a scale | Standard Deviation 47.87 |
| Treatment Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 6 (2-weeks Post-TKA) | 58.57 score on a scale | Standard Deviation 33.24 |
| Treatment Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 8 (4-weeks Post-TKA) | 40.29 score on a scale | Standard Deviation 26.56 |
| Treatment Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 10 (3-months Post-TKA) | 22.86 score on a scale | Standard Deviation 22.13 |
| Treatment Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 1 (Baseline) | 87.00 score on a scale | Standard Deviation 30.34 |
| Control Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 10 (3-months Post-TKA) | 29.38 score on a scale | Standard Deviation 21.05 |
| Control Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 1 (Baseline) | 111.31 score on a scale | Standard Deviation 38.78 |
| Control Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 11 (12-months Post-TKA) | 12.79 score on a scale | Standard Deviation 20 |
| Control Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 3 (Day of TKA) | 99.23 score on a scale | Standard Deviation 51.25 |
| Control Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 8 (4-weeks Post-TKA) | 51.94 score on a scale | Standard Deviation 30.83 |
| Control Group | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Visit 6 (2-weeks Post-TKA) | 81.13 score on a scale | Standard Deviation 38.98 |